ArticleAnalytical chemistry2026
Sensitivity Enhancement of Multiplex Lateral Flow Immunoassays by NIR-II Fluorescence and Thermal Contrast.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury.Biosensors & bioelectronics · 2026Article
- Rapid-Forming Conductive Antifouling Hydrogel Coating Enables Magnetically Guided Electrochemical POCT for Direct at‑Home Blood Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evolution of Next-Generation Multiplex Lateral Flow Immunoassays: From Engineered Nanomaterials to AI-Driven Detection.Biosensors · 2026Review
- Application Advances of Gold Nanoparticles in Cancer Theranostics: From Physicochemical Mechanisms to Multifunctional Nanoplatforms.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lateral flow assays (LFAs) are widely used for point-of-care (POC) diagnostics but often suffer from limited sensitivity and specificity compared with laboratory methods. Here, we present a multimodal LFA platform integrating colorimetric, photothermal, and second near-infrared window (NIR-II) fluorescence readouts for enhanced sensitivity and multiplexed detection. Gold nanorods were coupled with bright NIR-II emissive polymer dots to generate plasmon-enhanced fluorescence and efficient photothermal signals within a single probe. As proof-of-concept, carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) were selected as target biomarkers for breast cancer screening and broader cancer indication, respectively. Both thermometric and NIR-II fluorescence modes achieved comparable limits of detection for CA15-3 (0.40 and 0.42 U/mL) with a dynamic range of 0-100 U/mL, while CEA was quantified with a detection limit of 0.096 ng/mL. Multiplexed analysis on a single strip allowed simultaneous detection of CA15-3 and CEA with minimal cross-reactivity, and NIR-II fluorescence from test line 2 was intentionally designed to be invisible to the naked eye to avoid interference with rapid CA15-3 screening. Validation with clinical serum samples demonstrated a strong correlation with standard electrochemiluminescence immunoassays. This portable, low-cost platform demonstrates that NIR-II fluorescence and photothermal readouts can be harmonized for sensitive, selective, and multiplexed POC cancer biomarker detection. This universal and signal-amplifying concept can be further adapted to other targets of interest, offering a promising route toward next-generation LFAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.